Advertisement

Drugs

pp 1–6 | Cite as

Fexinidazole: First Global Approval

  • Emma D. DeeksEmail author
AdisInsight Report

Abstract

Fexinidazole Winthrop (hereafter referred to as fexinidazole) is a DNA synthesis inhibitor developed by the Drugs for Neglected Diseases initiative (DNDi), in collaboration with Sanofi, for the oral treatment of human African trypanosomiasis (HAT) [commonly known as ‘sleeping sickness’] and Chagas’ disease. The drug is a 5-nitroimidazole derivative first discovered by Hoechst AG (now part of Sanofi) and was identified by the DNDi in 2005 as having activity against Trypanosoma brucei gambiense and T. b. rhodesiense. Under Article 58 of Regulation (EC) no. 726/2004 (a regulatory mechanism for reviewing new medicines destined for use outside of the EU), fexinidazole has been granted a positive opinion by the EMA for the treatment of both the first-stage (haemo-lymphatic) and second-stage (meningo-encephalitic) of HAT due to T. b. gambiense (g-HAT) in adults and children aged ≥ 6 years and weighing ≥ 20 kg. This approval will facilitate and support marketing authorization application in endemic countries in 2019; following registration, fexinidazole will be distributed via the WHO to endemic countries for g-HAT. Phase 3 evaluation of fexinidazole for g-HAT is ongoing in the Democratic Republic of the Congo and Guinea and the drug is also in development for Chagas’ disease, with a study currently ongoing in Spain. Clinical development for visceral leishmaniasis is discontinued. This article summarizes the milestones in the development of fexinidazole leading to this first approval for g-HAT.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Von Geldern T, Harhay MO, Scandale I, et al. Kinetoplastid parasites. Top Med Chem. 2011;7:181–242.CrossRefGoogle Scholar
  2. 2.
    Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. Br Med Bull. 2012;104:175–96.CrossRefGoogle Scholar
  3. 3.
    Drugs for Neglected Diseases Initiative Foundation. Phase II/III studies show high efficacy and safety of fexinidazole, the first oral treatment for sleeping sickness [media release]. http://www.dndi.org. 04 Nov 2017.
  4. 4.
    Sanofi. Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment [media release]. 31 Jan 2018.Google Scholar
  5. 5.
    European Medicine Agency. Medicines for use outside the European Union. 2018. https://www.ema.europa.eu. Accessed 06 Dec 2018.
  6. 6.
    European Medicines Agency. Fexinidazole Winthrop: summary of opinion. https://www.ema.europa.eu/. Accessed 15 Nov 2018.
  7. 7.
    Sanofi. European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness [media release]. http://hugin.info/152918/R/2226012/873418.pdf. 17 Nov 2018.
  8. 8.
    US National Institutes of Health. ClinicalTrials.gov identifier NCT01980199. 2015. https://clinicaltrials.gov. Accessed 07 Jan 2019.
  9. 9.
    Drugs for Neglected Diseases initiative. Donors. 2018. https://www.dndi.org/donate/donors. Accessed 07 Jan 2019.
  10. 10.
    Drugs for Neglected Diseases Initiative Foundation. DNDi receives USD 60 million to fill research and development gaps for neglected patients [media release]. http://www.dndi.org. 02 Nov 2014.
  11. 11.
    Drugs for Neglected Diseases Initiative Foundation. DNDi receives support from Norwegian Agency for Development Cooperation for its research development on sleeping sickness [media release]. http://www.dndi.org. 22 May 2014.
  12. 12.
    World Health Organization. Human African trypanosomiasis. Symptoms, diagnosis and treatment. 2018. https://www.who.int/trypanosomiasis_african/disease/diagnosis/en/. Accessed 07 Jan 2019.
  13. 13.
    Torreele E, Trunz BB, Tweats D, et al. Fexinidazole – a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4(12):e923.CrossRefGoogle Scholar
  14. 14.
    Kaiser M, Bray MA, Cal M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011;55(12):5602–8.CrossRefGoogle Scholar
  15. 15.
    Burrell-Saward H, Harris AJ, de LaFlor R, et al. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. Int J Antimicrob Agents. 2017;50(2):203–9.CrossRefGoogle Scholar
  16. 16.
    Bahia MT, de Andrade IM, Martins TA, et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis. 2012;6(11):e1870.CrossRefGoogle Scholar
  17. 17.
    Francisco AF, Jayawardhana S, Lewis MD, et al. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Sci Rep. 2016;6:35351.CrossRefGoogle Scholar
  18. 18.
    Wyllie S, Patterson S, Stojanovski L, et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med. 2012;4(119):119re1.CrossRefGoogle Scholar
  19. 19.
    Dethoua M, Nzoumbou-Boko R, Truc P, et al. Evaluation of trypanocidal drugs used for human African trypanosomosis against Trypanosoma lewisi. Parasite. 2013;20:39.CrossRefGoogle Scholar
  20. 20.
    Jennings FW, Atouguia JM, Murray M. Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. Trop Med Int Health. 1996;1(5):590–8.CrossRefGoogle Scholar
  21. 21.
    Tweats D, Trunz BB, Torreele E. Genotoxicity profile of fexinidazole – a drug candidate in clinical development for human African trypanosomiasis (sleeping sickness). Mutagenesis. 2012;27(5):523–32.CrossRefGoogle Scholar
  22. 22.
    Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet. 2014;53(6):565–80.CrossRefGoogle Scholar
  23. 23.
    Mesu V, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144–54.CrossRefGoogle Scholar
  24. 24.
    Signorell A, Torrente M, Scherrer B, et al. Safety and efficacy of fexinidazole against rhodesiense human African trypanosomiasis: approach to conducting a clinical trial for a very rare, neglected disease [abstract no. PS2.088]. Trop Med Int Health. 2015;20(Suppl. 1):337.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations